{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:13:16Z","timestamp":1761894796232,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.bcmd.2008.09.003","type":"journal-article","created":{"date-parts":[[2008,11,10]],"date-time":"2008-11-10T03:29:23Z","timestamp":1226287763000},"page":"71-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Staging multiple myeloma patients with active disease using serum levels of \u03b22m-free HLA class I heavy chain together with IgM or platelet count"],"prefix":"10.1016","volume":"42","author":[{"given":"Federico","family":"Perosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Minoia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira","family":"Favoino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcella","family":"Prete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Dammacco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2008.09.003_bib1","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.bcmd.2008.09.003_bib2","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.3816\/CLM.2007.s.029","article-title":"Multiple myeloma: novel approaches for relapsed disease","volume":"8","author":"Lonial","year":"2007","journal-title":"Clin. Lymphoma Myeloma"},{"key":"10.1016\/j.bcmd.2008.09.003_bib3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10238-007-0134-y","article-title":"New therapies in multiple myeloma","volume":"7","author":"Merchionne","year":"2007","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.bcmd.2008.09.003_bib4","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/bjc.1980.273","article-title":"Serum beta 2-microglobulin in myelomatosis: potential value in stratification and monitoring","volume":"42","author":"Norfolk","year":"1980","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcmd.2008.09.003_bib5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.1983.tb02158.x","article-title":"Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging","volume":"55","author":"Bataille","year":"1983","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2008.09.003_bib6","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood.V63.2.468.468","article-title":"Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment\u2014a prospective study of 160 patients","volume":"63","author":"Bataille","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2008.09.003_bib7","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood.V75.4.823.823","article-title":"Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study","volume":"75","author":"Durie","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2008.09.003_bib8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/bjc.1983.13","article-title":"Evaluation of serum beta 2-microglobulin as a prognostic indicator in myelomatosis","volume":"47","author":"Child","year":"1983","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcmd.2008.09.003_bib9","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1365-2141.1990.tb07790.x","article-title":"Long-term prognostic value of serum beta 2 microglobulin in myelomatosis","volume":"75","author":"Cuzick","year":"1990","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2008.09.003_bib10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1200\/JCO.1986.4.1.80","article-title":"Prognostic factors and staging in multiple myeloma: a reappraisal","volume":"4","author":"Bataille","year":"1986","journal-title":"J Clin. Oncol."},{"key":"10.1016\/j.bcmd.2008.09.003_bib11","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V80.3.733.733","article-title":"C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system","volume":"80","author":"Bataille","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2008.09.003_bib12","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1046\/j.1365-2141.1999.01635.x","article-title":"Increased serum levels of beta2m-free HLA class I heavy chain in multiple myeloma","volume":"106","author":"Perosa","year":"1999","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2008.09.003_bib13","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0198-8859(99)00081-6","article-title":"Serum levels of beta-2-microglobulin-free heavy chain of HLA class I antigen in healthy individuals: relationship to their class I allotype","volume":"60","author":"Perosa","year":"1999","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.bcmd.2008.09.003_bib14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V72.1.219.219","article-title":"Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma","volume":"72","author":"Greipp","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2008.09.003_bib15","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood.V81.12.3382.3382","article-title":"Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma","volume":"81","author":"Greipp","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2008.09.003_bib16","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1182\/blood.V91.9.3366","article-title":"Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes","volume":"91","author":"Perez-Simon","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2008.09.003_bib17","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood.V86.11.4250.bloodjournal86114250","article-title":"Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities","volume":"86","author":"Tricot","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2008.09.003_bib18","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1182\/blood-2002-03-0749","article-title":"Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy","volume":"100","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2008.09.003_bib19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.1994.tb08304.x","article-title":"Bone marrow angiogenesis and progression in multiple myeloma","volume":"87","author":"Vacca","year":"1994","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2008.09.003_bib20","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood-2003-11-3811","article-title":"Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression","volume":"104","author":"Kumar","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2008.09.003_bib21","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2008.09.003_bib22","series-title":"Recent Advances in Haematology","first-page":"243","article-title":"Multiple myeloma, macroglobulinaemia and monoclonal gammopathies","author":"Durie","year":"1977"},{"key":"10.1016\/j.bcmd.2008.09.003_bib23","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1365-2141.2003.04456.x","article-title":"A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience","volume":"122","author":"Jacobson","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2008.09.003_bib24","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/0090-1229(80)90097-5","article-title":"Suppression of polyclonal immunoglobulins in multiple myeloma: relationship to the staging and other manifestations at diagnosis","volume":"17","author":"Pruzanski","year":"1980","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.bcmd.2008.09.003_bib25","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2008.09.003_bib26","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2008.09.003_bib27","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1182\/blood-2005-12-051458","article-title":"Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia","volume":"109","author":"Wierda","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2008.09.003_bib28","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1073\/pnas.94.5.1967","article-title":"Glutathione deficiency is associated with impaired survival in HIV disease","volume":"94","author":"Herzenberg","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.bcmd.2008.09.003_bib29","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2141.1985.tb07366.x","article-title":"Staging systems for multiple myeloma: a comparison","volume":"59","author":"Gassmann","year":"1985","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2008.09.003_bib30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2141.1988.tb07601.x","article-title":"Biochemical markers in multiple myeloma: a multivariate analysis","volume":"69","author":"Simonsson","year":"1988","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2008.09.003_bib31","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0002-9343(99)80081-3","article-title":"Plasma cell proliferation in monoclonal gammopathy: relations with other biologic variables\u2014diagnostic and prognostic significance","volume":"98","author":"Ffrench","year":"1995","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bcmd.2008.09.003_bib32","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1046\/j.1365-2141.1999.01651.x","article-title":"Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors","volume":"106","author":"Turesson","year":"1999","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2008.09.003_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1985.140","article-title":"The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis","volume":"52","author":"Cuzick","year":"1985","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcmd.2008.09.003_bib34","doi-asserted-by":"crossref","first-page":"5348","DOI":"10.1158\/1078-0432.CCR-06-2819","article-title":"Polyclonal immunoglobulin E levels are correlated with hemoglobin values and overall survival in patients with multiple myeloma","volume":"13","author":"Matta","year":"2007","journal-title":"Clin. Cancer Res."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979608002040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979608002040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:25:15Z","timestamp":1761049515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979608002040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S1079979608002040"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2008.09.003","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Staging multiple myeloma patients with active disease using serum levels of \u03b22m-free HLA class I heavy chain together with IgM or platelet count","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2008.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}